BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 7.98B |
| Revenue (ttm) | 8.71M |
| Net Income (ttm) | -519.95M |
| Shares Out | 138.63M |
| EPS (ttm) | -4.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $52.55 |
| Previous Close | $52.33 |
| Change ($) | 0.22 |
| Change (%) | 0.42% |
| Day's Open | 52.36 |
| Day's Range | 51.52 - 53.30 |
| Day's Volume | 496,519 |
| 52-Week Range | 26.17 - 73.50 |
PALO ALTO, Calif., July 27, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful ...
PALO ALTO, Calif., July 12, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines fo...
PALO ALTO, Calif., July 8, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for...
PALO ALTO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicine...
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.
BridgeBio Pharma Inc (NASDAQ: BBIO), through its affiliate QED Therapeutics Inc and Helsinn Group, has announced FDA approval for Truseltiq (infigratinib) under the accelerated approval program for chol...
PALO ALTO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicine...
PALO ALTO, Calif. & LUGANO, Switzerland--(BUSINESS WIRE)--BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug...
PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 4, 2021, th...
- Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American Society of Gene & Cell Therapy Annual Meeting, Enabling Anticipated Clinical Trials This Year - Prec...
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -35.63% and -95.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
–Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency...
Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition comp...
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate researc...
PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to...
PALO ALTO, Calif. and BUFFALO, N.Y., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the...
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance...
TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center t...
PALO ALTO, Calif. and EDMONTON, Alberta, April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Exce...
PALO ALTO, Calif. and PROVIDENCE, R.I., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genet...
PALO ALTO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on April 5, 2021...
At the start of March, BridgeBio Pharma Inc (NASDAQ: BBIO) won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A. In the middle of March, it announc...
- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equall...
It's worth putting a few of your eggs into this basket if you're worried about a big increase in prices.
– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept
Viking Global leader Andreas Holversen disclosed a stake in Orion Acquisition Corp. (NASDAQ:OHPAU) earlier this month, joining a growing number of investors who are seeing value opportunities in special...
Looking through the 13F reports filed by hedge funds over the past few weeks, it's clear that these investors are betting on technology.
PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021...
BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry (fosdenopterin) Injection to reduce the risk of mortality in patients with molybdenum ...
Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high inf...
BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory appr...
Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET Company to Host Webcast to Discuss Proof-of-Concept Data for ...
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i). ...
SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for ...
PALO ALTO, Calif. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 s...
PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 sha...
PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 20...
PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular an...
BridgeBio recently merged with Eidos, of which it previously owned 64%. AG10 is Eidos' lead asset.
PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of ...
PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the ...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the ...
Here's why the biggest biotech IPO of 2019 outshines all its peers.
PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 202...
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoin... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2019 |
| CEO Neil Kumar | Employees 385 |
| Stock Exchange NASDAQ | Ticker Symbol BBIO |
Financial Performance
In 2020, BBIO's revenue was $8.25 million, a decrease of -79.66% compared to the previous year's $40.56 million. Losses were -$448.72 million, 72.2% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is 81.63, which is an increase of 55.34% from the latest price.